NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Syngene International Limited (NSE: SYNGENE)

 
SYNGENE Technical Analysis
4
As on 24th Apr 2024 SYNGENE SHARE Price closed @ 694.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 740.46 & Sell for SHORT-TERM with Stoploss of 718.28 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

SYNGENESHARE Price

Open 704.75 Change Price %
High 711.30 1 Day -7.05 -1.01
Low 690.45 1 Week -16.85 -2.37
Close 694.00 1 Month -4.45 -0.64
Volume 949192 1 Year 73.90 11.92
52 Week High 839.10 | 52 Week Low 526.65
 
SYNGENE CURRENT MONTH FUTURE
Close 694.45
Contracts Traded 2985000
Open Intrest 1401000
Change In O.I -23.13 %
Lot Size 1000
SYNGENE CURRENT MONTH OPTION
Most Active Call 720.00
Most Active put 690.00
Highest O.I Buildup Call 800.00
Highest O.I Buildup Put 690.00
Expiry Date 2024-04-25
SYNGENE ALL MONTHS OPTIONS
For All SYNGENE Options Click Here
 
NSE INDIA Most Active Stocks
IDEA 13.10 -9.03%
SAIL 164.65 8.14%
YESBANK 25.45 -0.78%
TATASTEEL 165.55 2.73%
IRFC 149.00 0.85%
SOUTHBANK 29.10 1.04%
MRPL 248.70 10.75%
SUZLON 41.80 -0.12%
BEL 236.50 0.92%
RAMASTEEL 14.00 2.56%
 
NSE INDIA Top Gainers Stocks
ROML 63.05 19.98%
COMPUSOFT 35.20 19.93%
SHRADHA 78.55 19.83%
STEELCITY 102.95 19.78%
WEIZMANIND 142.25 19.59%
TEMBO 240.90 18.61%
CHENNPETRO 1075.00 15.82%
YUKEN 1180.65 13.81%
ORIENTCEM 230.50 12.85%
AEGISCHEM 604.50 12.41%
 
NSE INDIA Top Losers Stocks
BBL 3320.90 -51.12%
BBL 3320.90 -51.12%
BBL 3320.90 -51.12%
BBL 3320.90 -51.12%
IDEA 13.10 -9.03%
IDEA 13.10 -9.03%
IDEA 13.10 -9.03%
HUHTAMAKI 318.00 -8.19%
SHK 206.60 -7.64%
SHK 206.60 -7.64%
 
 
SYNGENE
Daily Charts
SYNGENE
Intraday Charts
Whats New @
Bazaartrend
SYNGENE
Free Analysis
 
SYNGENE Important Levels Intraday
RESISTANCE734.18
RESISTANCE721.29
RESISTANCE713.33
RESISTANCE705.36
SUPPORT682.64
SUPPORT674.67
SUPPORT666.71
SUPPORT653.82
 
SYNGENE Target April 2024
4th UP Target920.41
3rd UP Target851.5
2nd UP Target808.91
1st UP Target766.32
1st DOWN Target644.78
2nd DOWN Target602.19
3rd DOWN Target559.6
4th DOWN Target490.69
 
SYNGENE Weekly Target
4th UP Target849.75
3rd UP Target806.18
2nd UP Target779.25
1st UP Target752.32
1st DOWN Target675.48
2nd DOWN Target648.55
3rd DOWN Target621.62
4th DOWN Target578.05
 
SYNGENE Target2024
4th UP Target1328.01
3rd UP Target1127.07
2nd UP Target1002.86
1st UP Target878.66
1st DOWN Target524.24
2nd DOWN Target400.04
3rd DOWN Target275.83
4th DOWN Target74.89
 
 
SYNGENE Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is Below 30 Over Sold
MFI (14) MFI is 25.53 Sideways
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is -72.01 Sideways
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Long Buy 277.43
10 Day Avg Volume Traded 248.97 % More then 10 Day Average Volume
 
SYNGENE Other Details
Segment EQ
Market Capital 221879664640.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
SYNGENE Address
SYNGENE
 
SYNGENE Latest News
 
Your Comments and Response on Syngene International Limited
 
SYNGENE Business Profile
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company offers discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also provides exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company offers lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services. Further, it provides other drug modalities, which include peptides, oligonucleotide synthesis, antibody drug conjugate, PROTACs, and CAR T-cell therapy services. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter International Inc.; Amgen Inc.; PharmAust Limited; and HiMedia Laboratories. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited. Address: Biocon SEZ, Biocon Park,, Bengaluru, India, 560099
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service